MARKET

STTK

STTK

Shattuck Labs, Inc.
NASDAQ
0.9898
+0.0847
+9.36%
After Hours: 0.9431 -0.0467 -4.72% 17:02 05/15 EDT
OPEN
0.9002
PREV CLOSE
0.9051
HIGH
0.9898
LOW
0.9002
VOLUME
24.80K
TURNOVER
--
52 WEEK HIGH
11.76
52 WEEK LOW
0.6922
MARKET CAP
47.41M
P/E (TTM)
-0.7129
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at STTK last week (0505-0509)?
Weekly Report · 3d ago
Strategic Advancements and Promising Pipeline Developments Propel Shattuck Labs’ Buy Rating
TipRanks · 05/06 06:05
Shattuck Labs Advances SL-325 Program Amid Financial Progress
TipRanks · 05/06 04:05
Weekly Report: what happened at STTK last week (0428-0502)?
Weekly Report · 05/05 09:10
Shattuck Labs First Quarter 2025 Earnings: US$0.27 loss per share (vs US$0.37 loss in 1Q 2024)
Simply Wall St · 05/03 12:03
Cautious Optimism for Shattuck Labs: Hold Rating Amid Promising SL-325 Developments and Financial Stability
TipRanks · 05/02 10:29
Hold Rating for Shattuck Labs Amid Early-Stage Pipeline and Lack of Near-Term Catalysts
TipRanks · 05/02 10:29
TD Cowen Sticks to Its Buy Rating for Shattuck Labs (STTK)
TipRanks · 05/02 02:36
More
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.

Webull offers Shattuck Labs Inc stock information, including NASDAQ: STTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STTK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STTK stock methods without spending real money on the virtual paper trading platform.